SCHEMBL20117170

SCHEMBL20117170

CC(C)(C)OC(=O)N1CCN(c2noc(-c3ccnc(Cl)c3)n2)CC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.46
USP30 Q70CQ3 2/20 0.46
GPR119 Q8TDV5 5/20 0.44
POLB P06746 1/20 0.43
EPHA2 P29317 1/20 0.43
KDR P35968 1/20 0.43
EPHB4 P54760 1/20 0.43
PIK3CA P42336 2/20 0.43
CKS1B P61024 1/20 0.43
SKP1 P63208 1/20 0.43
SKP2 Q13309 1/20 0.43
TBK1 Q9UHD2 2/20 0.43
IKBKE Q14164 1/20 0.43
DDB1 Q16531 1/20 0.42
CRBN Q96SW2 1/20 0.42
S1PR1 P21453 1/20 0.42
SCD5 Q86SK9 1/20 0.42
CHRNA7 P36544 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20117140 0.85 PIK3CA (0.51) ACHEUSP30GPR119PIK3CACKS1B
SCHEMBL20116315 0.85 TBK1 (0.49) ACHEUSP30GPR119PIK3CACKS1B
SCHEMBL20116978 0.83 ACHE (0.47) ACHEUSP30GPR119PIK3CACKS1B
SCHEMBL20676674 0.82 MAPT (0.43) S1PR1
SCHEMBL20676652 0.82 USP30 (0.43) ACHEUSP30GPR119PIK3CATBK1
SCHEMBL387529 0.82 CKS1B (0.56) ACHEGPR119PIK3CACKS1BSKP1
SCHEMBL20676316 0.81 USP30 (0.42) ACHEUSP30GPR119EPHA2KDR
SCHEMBL20676481 0.81 S1PR1 (0.54) CKS1BSKP1SKP2S1PR1
SCHEMBL391852 0.80 GBA1 (0.57) ACHEGPR119POLBPIK3CACKS1B
SCHEMBL20676484 0.79 S1PR1 (0.41) S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 ACHE 2/4885USP30 3526/4885GPR119 2922/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 ACHE 2/4885USP30 3526/4885GPR119 2922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.